Galectin Therapeutics Inc. (NASDAQ: GALT)
$2.53
+0.1500 ( +6.30% ) 116.3K
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Market Data
Open
$2.53
Previous close
$2.38
Volume
116.3K
Market cap
$138.59M
Day range
$2.38 - $2.53
52 week range
$1.35 - $4.27
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 20, 2024 |
8-k | 8K-related | 15 | May 15, 2024 |
10-q | Quarterly Reports | 62 | May 15, 2024 |
4 | Insider transactions | 1 | Apr 30, 2024 |
4 | Insider transactions | 1 | Apr 25, 2024 |
5 | Other | 1 | Apr 25, 2024 |
4 | Insider transactions | 1 | Apr 25, 2024 |
4 | Insider transactions | 1 | Apr 22, 2024 |
4 | Insider transactions | 1 | Apr 09, 2024 |
8-k | 8K-related | 15 | Mar 29, 2024 |